|
DFB Pharmaceuticals seeks to in-license, develop or acquire products and technologies that complement our businesses and capabilities. We offer partners our significant experience and expertise in product development, manufacturing, marketing, sales and distribution. Of particular interest are concepts that complement our current product portfolio or offer the opportunity to expand into new, synergistic markets.
Healthpoint develops and markets prescription pharmaceutical and biologic products in the fields of wound care and surgery. Each of these businesses has its own proprietary marketing and sales organization.
Healthpoint Tissue Management develops and markets prescription drugs and biologics for the treatment of wounds. Tissue Management's marketing efforts target hospitals and extended-care facilities with a focus on chronic wounds, such as pressure, venous and diabetic ulcers, and on partial-thickness wounds associated with incontinence, perineal dermatitis, burns and other trauma.
Healthpoint Specialty currently develops and markets unique products for skin asepsis and topical anesthesiology. Healthpoint Specialty aims to be a leader in surgical pharmaceuticals and biologics by offering products for use before, during and after surgery.
DPT offers a wide range of services and solutions that are focused primarily on semi-solid and liquid dosage forms. Based on customer needs, DPT solutions are available on a fully integrated or stand-alone basis.
Phyton Biotech's specialty is production of sophisticated human therapeutic agents through plant cell fermentation, which makes us the undeniable choice for your protein of interest. We provide rapid scale-up resulting in the shortest possible timeline for development of your product.
To discuss in-licensing opportunities, please contact Maxwell Lea at the email address below.
Maxwell Lea
New Business Development
maxwell.lea@dfb.com
|
